Can ashwagandha lower blood glucose or help someone with diabetes? A new meta-analysis published on 25 August 2026 pooled eleven randomised trials and provides a more reliable answer than isolated claims: there was a small signal for fasting blood glucose, but no conclusive effect on HbA1c, and the overall certainty of evidence was rated very low. The authors explicitly stated that the findings do not support clinical recommendations.

That distinction matters. A change in one laboratory marker does not mean a supplement treats diabetes, prevents its complications or can replace medication. This guide explains what was actually measured, why the findings remain uncertain and which precautions people in Morocco should take before combining ashwagandha with diabetes treatment.

Short answer: ashwagandha is not a diabetes treatment

The 2026 meta-analysis pooled eleven trials involving 667 adults. Compared with placebo, the mean difference in fasting blood glucose was −3.09 mg/dL, with a confidence interval from −5.61 to −0.58. For HbA1c, calculated from only three trials, the mean difference was −0.05 percentage points and the confidence interval ranged from −0.47 to +0.36, making the result inconclusive.

The authors rated the certainty of both outcomes as very low. Trials differed substantially in participants, duration and ashwagandha preparation. The small average change in fasting glucose therefore proves neither a durable effect, a reduction in complications, nor efficacy for a particular person.

Fasting glucose and HbA1c do not measure the same thing

Fasting blood glucose measures glucose at one point after at least eight hours without food. It can vary with sleep, stress, illness, recent activity and sampling conditions. A statistical difference in this measure must be interpreted according to its size, consistency and clinical context.

HbA1c broadly reflects average blood glucose over the previous three months. It is used for diagnosis and monitoring, with some individual limitations. A small fasting-glucose signal without a conclusive HbA1c result does not demonstrate sustained glycaemic control.

What the new meta-analysis can — and cannot — conclude

Pooling eleven trials increases the available information but does not automatically repair weaknesses in the underlying studies. The 667 participants were not one uniform population: some were healthy and others had different metabolic profiles. Extracts, amounts and durations varied, and heterogeneity in the fasting-glucose result was substantial.

Exploratory analyses established neither a dose-response relationship nor an optimal duration. It would therefore be misleading to turn the pooled average into a dose, promise more from a higher amount or apply the finding to any powder or capsule. The analysis mainly supports the need for better trials in clearly defined populations.

Why the older studies were already insufficient

A frequently cited trial published in 2000 studied glucose in only six people with mild type 2 diabetes for thirty days using root powder. A separate six-person group concerned lipids. Such a small sample, short duration and limited comparator description cannot establish a reliable treatment.

Another randomised trial published in late 2025 involved forty adults aged 50–70 who were considered generally healthy and primarily assessed safety over 180 days. Some glycaemic measures changed, but the study was not designed to demonstrate diabetes treatment and its small size severely limits subgroup analysis.

Diabetes, prediabetes and normal glucose are different situations

Someone with diagnosed diabetes has a care plan, individual targets and often medication. Prediabetes requires laboratory confirmation and a suitable prevention strategy. A person without a diagnosis should not interpret fatigue, thirst or weight change as proof of high glucose and start a supplement at random.

Diagnosis is not based on how someone feels after a capsule or on one unusual home reading. A professional selects and repeats the necessary tests. In Morocco as elsewhere, unusual thirst, frequent urination, unexplained weight loss, blurred vision or persistent fatigue warrant assessment rather than self-experimentation.

The main practical risk: combining it with treatment

NCCIH states that ashwagandha may interact with some diabetes medicines. If a product truly changes glucose in someone already treated, the combination may make control less predictable and could contribute to hypoglycaemia. Never reduce, stop or reschedule prescribed treatment to test a supplement.

Show the doctor or pharmacist the complete label: botanical name, plant part, extract type, amount per serving and other ingredients. Ask how glucose should be monitored and which signs require stopping. Shaking, sweating, confusion, weakness or faintness in a treated person require action according to their medical team’s plan.

Other precautions still matter beyond blood glucose

Ashwagandha can cause drowsiness, digestive discomfort, diarrhoea or vomiting. Rare liver injuries have been reported. Pregnancy, breastfeeding, upcoming surgery and certain thyroid or autoimmune disorders are situations in which it should be avoided or discussed with a professional.

Interactions are also possible with blood-pressure medicines, sedatives, anti-seizure drugs, immunosuppressants and thyroid hormones. The absence of a serious event in a short trial does not guarantee the safety of every preparation, combination or prolonged use.

Before buying in Morocco: a checklist without medical promises

Reject products claiming to “cure diabetes,” replace metformin or normalise HbA1c without monitoring. Check for Withania somnifera, whether root or leaf is used, powder or extract, stated standardisation, amount per serving, batch, date and responsible operator. A milligram number proves neither equivalence to a trial nor quality.

Do not buy several blood-sugar products at the same time: ingredients may be duplicated and any reaction becomes difficult to identify. If a professional agrees to a trial, maintain the agreed medication, diet and monitoring and draw no conclusion from one reading.

Bottom line

The synthesis published on 25 August 2026 found a modest average reduction in fasting glucose but no conclusive HbA1c effect. Substantial heterogeneity and very low certainty prevent turning this finding into treatment advice, a dose or a commercial promise.

People with diabetes or prediabetes should not use ashwagandha to replace or adjust treatment. Any possible use should be decided with the prescriber or pharmacist based on the exact product and a monitoring plan. For everyone else, ashwagandha neither diagnoses nor prevents diabetes on its own.

Frequently asked questions

Does ashwagandha lower blood glucose?

A 2026 meta-analysis found a small average reduction in fasting glucose with very low certainty, but no conclusive HbA1c effect. This does not establish a diabetes treatment.

Can it replace metformin or another medicine?

No. Never stop or alter prescribed treatment to take ashwagandha. Evidence is insufficient and interactions with some diabetes medicines are possible.

Could ashwagandha plus diabetes medication cause hypoglycaemia?

The combination may make glucose less predictable if ashwagandha has an effect in that person. Ask the prescriber or pharmacist before use and follow the agreed monitoring plan.

What is the difference between fasting glucose and HbA1c?

Fasting glucose is a point-in-time measurement after at least eight hours without food. HbA1c broadly reflects the previous three-month average. A result in one does not guarantee the same result in the other.

Can someone with prediabetes take ashwagandha?

Do not treat it as a proven prevention strategy. Seek advice with the exact product label, particularly with other medicines or conditions, and prioritise monitoring and measures recommended by your clinician.

Educational content: this is not a diagnosis or prescription and does not replace professional healthcare advice.

Sources